AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00839956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00839956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03656250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT scans
Description: (approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
Study NCT02091115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dairy drink with probiotic culture
Description: The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
Study NCT02091115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy drink
Study NCT00661297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg Vardenafil to be taken 1 h prior to sexual attempt
Study NCT00661297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00373451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab + UFH
Description: Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)
Study NCT00373451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
Study NCT00373451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: i.v. bolus of 70 units/kg/body weight of unfractionated heparin
Study NCT00003485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antineoplaston A10, antineoplaston AS2-1 (ANP)
Description: Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT03573193 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ridge preservation
Description: Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP).
Study NCT03573193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ridge preservation
Description: Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP).
Study NCT04134624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sepsis care bundle
Description: Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
Study NCT02834299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Guided Self-Help
Description: DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
Study NCT02834299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Unguided Self-Help
Description: DBT self-help manual without any therapy sessions for 12 weeks
Study NCT02834299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Esteem-Focused Unguided Self-Help
Description: Self-esteem focused self-help manual without any therapy sessions for 12 weeks
Study NCT02809560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced sputum method using hypertonic serum
Description: Collection of expectoration in sterile vial, conserved in ice all along the examination
Study NCT02809560 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Induced sputum method using hypertonic serum
Description: Collection of expectoration in sterile vial, conserved in ice all along the examination
Study NCT00006462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT01607476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11 PiB
Description: One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
Study NCT01607476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C11 PiB
Description: One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
Study NCT01607476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18 Flutametamol
Description: One time intravenous administration of 3-7 mCi F18 Flutametamol.
Study NCT01607476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F18 Flutametamol
Description: One time intravenous administration of 3-7 mCi F18 Flutametamol.
Study NCT01024738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Rinse mouth twice a day
Study NCT04076501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen application
Description: Oxygen application Supplemental oxygen via mask
Study NCT04076501 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham room air
Description: Room air applied via mask
Study NCT03408366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
Study NCT03408366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG
Description: ICG will be injected intravenously ICG is a fluorescent iodide dye.
Study NCT03408366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectrum NIR imaging system
Description: The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
Study NCT03806036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 300.000 I.U single dose of VIT D IM injection
Study NCT03806036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate
Description: 100mg daily for 5 days starting from third day of menstruation
Study NCT03806036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: 100mg daily for 5 days starting from third day of menstruation
Study NCT00670956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: 12 mg intramuscularly x 2 doses 24 hours apart
Study NCT00670956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO: IM x 2 doses 24 hours apart
Study NCT00805909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0401
Description: 5 daily infusions with escalating doses of NI-0401
Study NCT02323490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with microfractures
Description: following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
Study NCT02323490 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: without microfractures
Description: standard procedure meniscal repair without augmentation.
Study NCT02494713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix
Description: Subcutaneous injection, once/month for 4 months
Study NCT02494713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
Study NCT02494713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketoconazole
Description: 400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
Study NCT02494713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
Study NCT02494713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Estramustine
Description: 280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
Study NCT05131906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait task and activity of daily living task
Description: use of lasers on shoes to potentially minimize freezing of gait
Study NCT03629158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIMB intervention
Description: The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health.
Study NCT02161874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3 with DCD tapered Prevail implant
Description: T3 with DCD implant with Certain (internal) connection and platform-switch design
Study NCT02161874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanotite Certain tapered implant
Description: Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
Study NCT03784261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Salirumab
Description: To examine the effects of salirumab in RA patients
Study NCT03784261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tocilizmab
Description: To examine the effects of tocilizmab in RA patients
Study NCT03784261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Abatacept
Description: To examine the effects of abatacept in RA patients
Study NCT04172298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham electroacupuncture (EA) session
Description: The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
Study NCT04172298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zusanli session
Description: The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
Study NCT04172298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shaohai session
Description: The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
Study NCT01839942 — intervention group
Intervention type: PROCEDURE
Intervention: hernia gap closure
Description: type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
Study NCT01839942 — intervention group
Intervention type: PROCEDURE
Intervention: extracorporal suturing of gap
Description: ventral hernia gap is sutured extracorporally
Study NCT00167206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant
Description: Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
Study NCT00167206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thymic Shielding During Radiation
Description: protecting the thymus during total body radiation (450 cGy administered)
Study NCT00167206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
Study NCT00167206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine
Description: Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
Study NCT00545649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education
Study NCT00545649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT02213731 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Holter monitoring
Description: Subjects will wear holter monitors at baseline, 6 months and 12 months.
Study NCT03497403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation control
Description: After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
Study NCT03497403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation experimental
Description: After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
Study NCT02250053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT03965338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: fMRI
Description: Screening
Study NCT03656224 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01943942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Reference product
Study NCT01943942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Test product
Study NCT02274155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40 antibody administration
Description: Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
Study NCT02274155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor
Study NCT02251249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol concentration time curve from 0 to 120 min
Description: It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
Study NCT02251249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol concentration time curve from 0 to 120 min
Description: It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
Study NCT01885169 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flumist®
Description: The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
Study NCT01460225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lubiprostone
Description: 24 micrograms twice daily for 1 week
Study NCT03016351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
Study NCT03016351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
Study NCT04121897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist Education and Massage for Parents of Extremely Preterm Infants
Description: TEMPO includes these components:~* Early Parent Education Session~* Weekly Parent Education Sessions~* Infant Massage Parent Education Sessions~* Discharge Parent Education Session~* Parent Education Post-Discharge~* Bi-weekly emails (or texts)~* 2 Month Follow-up Massage Review Session
Study NCT03394677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.5% ointment
Description: Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
Study NCT03394677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Placebo comparator - ointment twice daily (BID) for 4 weeks.
Study NCT01306214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose
Study NCT01306214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose
Study NCT01306214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose
Study NCT01306214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose
Study NCT01306214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose once daily
Study NCT01306214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose once daily
Study NCT00779753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Solution with different amount of Lysine
Description: The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
Study NCT04116775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant
Description: A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
Study NCT04116775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
Study NCT04116775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Daily oral dose.
Study NCT02954588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxamine
Study NCT02954588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02874716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculosis Program (PPIA)
Description: The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.